Intraoperative use of non-steroidal anti-inflammatory drugs has no impact on melanoma survival

July 14, 2020

Abstract

The aim of the study was to investigate if there was an association between intraoperative NSAID use and recurrence or survival. A cohort of patients who underwent sentinel lymph node biopsy for the treatment of cutaneous melanoma was retrospectively recruited. After applying inclusion and exclusion criteria, 516 were included (NSAIDs =307). The 10-year melanoma-specific survival was 63.2%. Log rank test showed no statistically significant differences in time to treatment failure, melanoma-specific survival, disease-free survival, and overall survival between the study groups. The current study did not support the use of intraoperative NSAIDs in preventing death or recurrence in patients with melanoma.

Source:

Araujo, B. L., Oliveira, J. L., Rezende, J. F., Noguera, W. S., Melo, A. C., & Thuler, L. C. (2020). Impact of Non-steroidal Anti-inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study. Cancer Investigation, 1-33. doi:10.1080/07357907.2020.1793351

https://www.tandfonline.com/doi/abs/10.1080/07357907.2020.1793351